Trade
Divi's Laboratories share price
Moderate risk
You have to be logged in to add this to Watchlist.- ₹6,925.45(1.31%)July 13, 2026 15:28:46 PM IST
- NSE
- BSE
- Vol : 279.36 K (NSE + BSE)Last 20 day avg : 355.66 K
Divi's Laboratories is trading 1.31% upper at Rs 6,925.45 as compared to its last closing price. Divi's Laboratories has been trading in the price range of 6,955.00 & 6,791.00. Divi's Laboratories has given 6.94% in this year & 1.17% in the last 5 days. Divi's Laboratories has TTM P/E ratio 61.42 as compared to the sector P/E of 35.48.There are 27 analysts who have initiated coverage on Divi's Laboratories. There are 6 analysts who have given it a strong buy rating & 7 analysts have given it a buy rating. 6 analysts have given the stock a sell rating.The company posted a net profit of 751.00 Crores in its last quarter.Listed peers of Divi's Laboratories include Dr Reddy's Laboratories (-0.88%), Torrent Pharmaceuticals (0.91%), Cipla (-0.78%).The Mutual Fund holding in Divi's Laboratories was at 13.42% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Divi's Laboratories was at 20.29% in 31 Mar 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 13, 2026, 04:38 PM UTC
- BetaLow volatility0.74Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.44Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation5.84The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Divi's Laboratories News
Divi's Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dr Reddy's Laboratories | 1,234.60 | -0.88 | 1,03,044.26 | 18.63 | 3.14 | 0.63 | 2.34 |
| Torrent Pharmaceuticals | 4,948.05 | 0.91 | 1,67,736.57 | 67.32 | 17.1 | 0.83 | 17.62 |
| Cipla | 1,427.50 | -0.78 | 1,15,319.91 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | 1,924.05 | -0.58 | 4,61,633.17 | 36.24 | 5.77 | 0.92 | 0.50 |
| Lupin | 2,485.00 | -0.44 | 1,13,610.91 | 28.78 | 5.59 | 0.57 | 11.80 |
Mutual Fund Ownership
View allDivi's Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-23 | Audited Results & Dividend |
| 2026-02-11 | Quarterly Results |
| 2025-11-07 | Quarterly Results |
| 2025-08-06 | Quarterly Results |
| 2025-05-17 | Audited Results & Dividend |
About the company Divi's Laboratories
- IndustryBiotechnology & Drugs
- ISININE361B01024
- BSE Code532488
- NSE CodeDIVISLAB
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
Divi's Laboratories Share Price FAQs
Divi's Laboratories is trading at 6925.45 as on Mon Jul 13 2026 09:58:46. This is 1.31% upper as compared to its previous closing price of 6835.70.
The market capitalization of Divi's Laboratories is 183840.87 Cr as on Mon Jul 13 2026 09:58:46.
The average broker rating on Divi's Laboratories is Hold. The breakup of analyst rating is given below -
- 6 analysts have given a strong buy rating
- 7 analysts have given a buy rating
- 5 analysts have given a hold rating
- 6 analysts have given a sell rating
- 3 analysts have given a strong sell rating
The 52 wk high for Divi's Laboratories is 7077.70 whereas the 52 wk low is 5637.50
Divi's Laboratories can be analyzed on the following key metrics -
- TTM P/E: 61.42
- Sector P/E: 35.48
- Dividend Yield: 0.44%
- D/E ratio: 0.00
Divi's Laboratories reported a net profit of 2568.00 Cr in 2026.
The Mutual Fund Shareholding was 13.42% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
Divi's Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.